These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 9248728)
1. Molecular basis and promise of genetic therapy for diabetic dyslipidaemia: studies in an animal model of diabetes. Chan L; Kobayashi K Diabetologia; 1997 Jul; 40 Suppl 2():S155-6. PubMed ID: 9248728 [No Abstract] [Full Text] [Related]
2. Adenovirus-mediated gene transfer of human lipoprotein lipase ameliorates the hyperlipidemias associated with apolipoprotein E and LDL receptor deficiencies in mice. Zsigmond E; Kobayashi K; Tzung KW; Li L; Fuke Y; Chan L Hum Gene Ther; 1997 Nov; 8(16):1921-33. PubMed ID: 9382958 [TBL] [Abstract][Full Text] [Related]
3. The effects of VEGF-A on atherosclerosis, lipoprotein profile, and lipoprotein lipase in hyperlipidaemic mouse models. Heinonen SE; Kivelä AM; Huusko J; Dijkstra MH; Gurzeler E; Mäkinen PI; Leppänen P; Olkkonen VM; Eriksson U; Jauhiainen M; Ylä-Herttuala S Cardiovasc Res; 2013 Sep; 99(4):716-23. PubMed ID: 23756254 [TBL] [Abstract][Full Text] [Related]
4. The therapeutic role of very low-density lipoprotein receptor gene in hyperlipidemia in type 2 diabetic rats. Yuan G; Liu Y; Sun T; Xu Y; Zhang J; Yang Y; Zhang M; Cianflone K; Wang DW Hum Gene Ther; 2011 Mar; 22(3):302-12. PubMed ID: 21087152 [TBL] [Abstract][Full Text] [Related]
5. Deficiency of the very low-density lipoprotein (VLDL) receptors in streptozotocin-induced diabetic rats: insulin dependency of the VLDL receptor. Iwasaki T; Takahashi S; Takahashi M; Zenimaru Y; Kujiraoka T; Ishihara M; Nagano M; Suzuki J; Miyamori I; Naiki H; Sakai J; Fujino T; Miller NE; Yamamoto TT; Hattori H Endocrinology; 2005 Aug; 146(8):3286-94. PubMed ID: 15878964 [TBL] [Abstract][Full Text] [Related]
6. [Neonatal hyperlipemia due to lipoprotein lipase deficiency]. Thouvenot JP; Ghisolfi G; Douste-Blazy L Ann Biol Clin (Paris); 1973; 31(2):127-8. PubMed ID: 4356110 [No Abstract] [Full Text] [Related]
7. Lipoprotein subclass profiles of hyperlipidemic diabetic mice measured by nuclear magnetic resonance spectroscopy. Hammad SM; Powell-Braxton L; Otvos JD; Eldridge L; Won W; Lyons TJ Metabolism; 2003 Jul; 52(7):916-21. PubMed ID: 12870170 [TBL] [Abstract][Full Text] [Related]
8. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Lambert G; Jarnoux AL; Pineau T; Pape O; Chetiveaux M; Laboisse C; Krempf M; Costet P Endocrinology; 2006 Oct; 147(10):4985-95. PubMed ID: 16794006 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of apolipoprotein E prevents development of diabetic hyperlipidemia in transgenic mice. Yamamoto K; Shimano H; Shimada M; Kawamura M; Gotoda T; Harada K; Ohsuga J; Yazaki Y; Yamada N Diabetes; 1995 May; 44(5):580-5. PubMed ID: 7729619 [TBL] [Abstract][Full Text] [Related]
12. The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. Kobayashi K; Forte TM; Taniguchi S; Ishida BY; Oka K; Chan L Metabolism; 2000 Jan; 49(1):22-31. PubMed ID: 10647060 [TBL] [Abstract][Full Text] [Related]
13. Extravascular modified lipoproteins: a role in the propagation of diabetic retinopathy in a mouse model of type 1 diabetes. Yu JY; Du M; Elliott MH; Wu M; Fu D; Yang S; Basu A; Gu X; Ma JX; Aston CE; Lyons TJ Diabetologia; 2016 Sep; 59(9):2026-35. PubMed ID: 27306616 [TBL] [Abstract][Full Text] [Related]
14. Lipoprotein lipase in experimental diabetic rats: beneficial effect of vanadate treatment. Levy E; Bendayan M Diabete Metab; 1991; 17(1):44-8. PubMed ID: 1868959 [TBL] [Abstract][Full Text] [Related]
15. [Activity changes of macrophage lipoprotein receptor in diabetic mice]. Wang H Zhonghua Yi Xue Za Zhi; 1991 May; 71(5):271-3. PubMed ID: 1650645 [No Abstract] [Full Text] [Related]
16. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype. Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933 [TBL] [Abstract][Full Text] [Related]